# PeptideEmails.com — SEO Blog Playbook & SOPs

*Master operating document for building the PeptideEmails.com blog into the topical authority for peptide/GLP-1 email marketing.*

Owner: Harry Garstka · Last updated: 2026-08-07 · Companion files: [`01-article-roadmap.csv`](01-article-roadmap.csv) · [`02-content-architecture.md`](02-content-architecture.md)

---

## 1. The strategic thesis (read this first)

The keyword data tells us exactly what game we are playing. **This is not a search-volume play. It is a topical-authority + AI-citation (GEO) play.**

| Layer | Example terms | Real monthly US volume | What it means for us |
|---|---|---|---|
| **Substance / entity demand** | tirzepatide (1M), semaglutide (368K), cjc-1295 (49.5K), compounded semaglutide (33K), research peptides (14.8K) | Enormous | Not our buyers (consumers/patients) — but the **entities** every AI model and Google associate with our niche. We must own the *brand-marketing* angle on them. |
| **Category / infrastructure demand** | high risk merchant account (1.9K), email deliverability (1K), email warm up (720), abandoned cart email (720), fluentcrm (590), sendlane (480), klaviyo alternatives (390), omnisend vs klaviyo (260), dmarc setup (210) | Modest, low competition | Adjacent buyers researching the *problem*. Winnable, and they interlink beautifully to money pages. |
| **Exact-match buyer intent** | peptide email marketing, email marketing for supplement brands, GLP-1 email marketing, klaviyo for supplements | ~Zero measured, ~zero competition | **The whitespace.** Almost no one searches it monthly, but the few who do are our single highest-value prospects. We should be the *only* comprehensive resource — in Google *and* in ChatGPT/Perplexity/Gemini answers. |

**Three consequences that shape everything below:**

1. **Win by depth and entity coverage, not by chasing volume.** When a peptide brand owner (or the AI they ask) researches "can I use Klaviyo for peptides," "how do I market tirzepatide compliantly," or "best email platform for supplement brands," PeptideEmails.com must be the most complete, most-cited answer on the internet. Topical authority is earned by covering the *entire* topic, not one post.

2. **The competitor wedge is our spine.** The competitor at **peptideemails.co** recommends Klaviyo/Omnisend. Our entire thesis (peptideemails.com) is that those platforms *ban* peptide senders and you need Sendlane or self-hosted infrastructure. Every comparison and platform article rides the same demand but lands on the opposite, better-defended conclusion — and links to us. We capture their keyword traffic and out-truth them.

3. **Optimize for GEO (Generative Engine Optimization) as hard as for Google.** In a near-zero-volume niche, a huge share of real buyer discovery now happens inside AI assistants. Entity-rich, well-structured, citable content (clear definitions, comparison tables, FAQ schema, named entities) is what gets quoted. Every SOP below bakes this in.

---

## 2. Site architecture: hub-and-spoke, everything points home

We use a **pillar → cluster → spoke** model. Full map in [`02-content-architecture.md`](02-content-architecture.md). In summary:

```
                          HOMEPAGE (peptideemails.com)
                        "Peptide email marketing agency"
                                     ▲
        ┌───────────┬───────────┬────┴────┬───────────┬───────────┐
     PILLAR 1    PILLAR 2    PILLAR 3   PILLAR 4    PILLAR 5    PILLAR 6
     Email       Platforms/  FDA &      Email       Marketing   Deliver-
     Marketing   Infra       Compliance Flows       by          ability &
     for Peptide (Sendlane/  (21 CFR/   (Welcome/   Substance   Sending
     Brands      bans/self-  warning    cart/       (GLP-1/     Infra
     [MONEY HUB] hosted)     letters)   winback)    tirzep...)  (DKIM...)
        │           │           │          │           │           │
     spokes      spokes      spokes     spokes      spokes      spokes
     (10-16 supporting articles per pillar, each linking UP to its pillar,
      SIDEWAYS to 2-3 sibling spokes, and the pillar linking to HOMEPAGE)
```

**Rules of the structure:**

- **Every pillar page links to the homepage** with the exact-match or near-match anchor ("peptide email marketing agency," "done-for-you peptide email systems").
- **Every spoke links up to its pillar** (contextual anchor) and **sideways to 2–3 sibling spokes**. Never orphan a post.
- **Pillars link to each other** where topically adjacent (Platforms ↔ Deliverability ↔ Compliance).
- **The money hub (Pillar 1) is the internal-link sink** — the most linked-to page on the blog after the homepage. Every commercial-intent spoke funnels here, and this hub funnels to the booking CTA.
- **URL structure:** `/blog/{slug}` for all articles; pillars can optionally live at `/{topic}` (e.g. `/peptide-email-marketing`) if you want them treated as landing pages. Keep slugs short, keyword-first, hyphenated, no dates in URL.

---

## 3. The publishing sequence (6 waves, priority order)

We do **not** build all 100 at once. We build in waves that establish each pillar's spine first, then thicken. Full per-article sequence is in the CSV (`#` column = global priority order). Wave logic:

| Wave | Articles | Goal | Focus |
|---|---|---|---|
| **Wave 1 — Foundation** | #1–15 | Stand up all 6 pillar pages + the highest-intent money spokes | The 6 pillars, "email marketing for peptide brands complete guide," the core platform-ban and Sendlane pieces, the flagship comparison (Klaviyo vs Sendlane for peptides). |
| **Wave 2 — Commercial capture** | #16–35 | Own every platform comparison & "can I use X for peptides" query | vs pages, alternatives pages, platform-for-peptides pages, high-risk merchant/deliverability commercial terms. |
| **Wave 3 — Compliance moat** | #36–55 | Become the compliance reference no competitor can match | 21 CFR 201.128, warning-letter teardowns, research-only language, COA trust, disease-claim guides. This is our defensibility. |
| **Wave 4 — Flows & retention** | #56–72 | Rank for every flow/automation a peptide store needs | Welcome, abandoned cart, replenishment/reorder, winback, launch, education series — each peptide/supplement-specific. |
| **Wave 5 — Entity & substance authority** | #73–88 | Attach our brand to the giant substance entities | "How to market/sell/build a brand around" tirzepatide, semaglutide, retatrutide, BPC-157, etc. — compliant brand-owner angle. |
| **Wave 6 — Audience & long-tail depth** | #89–100 | Segment landing content + fill remaining gaps | Compounding pharmacy, telehealth, research labs, creators/influencers, plus deliverability/infra long-tail. |

**Cadence guidance:** At 2 articles/week you complete the 100 in ~12 months; at 4/week in ~6 months. Front-load Waves 1–2 (do these at 3–4/week) because they carry the commercial intent; Waves 3–6 can run at 2/week. Re-sequence freely inside a wave based on what's converting — but finish each pillar's spine before thickening it.

---

## 4. SOP A — Keyword & topic validation (before writing anything)

Run for **every** article before it enters the queue. ~15 min each.

1. **Confirm the primary keyword.** One primary per article (from the CSV). Do not cannibalize — two articles must never target the same primary. Maintain the CSV as the single source of truth.
2. **Pull live volume + SERP.** Re-check volume (it drifts) and read the top 5 results. Ask: *Is the intent informational, commercial, or transactional? Who currently ranks — and can we out-depth them?* In this niche the answer is almost always yes because coverage is thin.
3. **Harvest "People Also Ask" + related searches.** These become your H2s and FAQ block. Screenshot/save them into the article brief.
4. **List the entities you must name** (see SOP D). Pull the substance names, platform names, regulations, and standards that Google/AI expect to co-occur with this topic.
5. **Decide the internal-link targets now** (1 pillar up, 2–3 siblings, 1 money page). Write them into the brief so linking isn't an afterthought.
6. **Set the CTA** appropriate to funnel stage (see SOP E).

Output of this SOP = a one-page **article brief** (template in §9).

---

## 5. SOP B — On-page article structure (the template)

Every article follows this skeleton. Consistency compounds authority and makes AI extraction reliable.

1. **H1** = primary keyword, naturally phrased. One H1 only.
2. **TL;DR block** (2–4 sentences or bullets) at the very top. This is the single most important element for GEO — it's what AI assistants quote and what busy buyers read. State the answer, including our contrarian conclusion where relevant. *(The competitor does this well; match it.)*
3. **Intro (2–3 short paragraphs)** — name the problem in the reader's language, state who this is for, promise the payoff. Include the primary keyword in the first 100 words.
4. **Body H2s** driven by the PAA/related-search harvest. Use descriptive, question-shaped H2s ("Will Klaviyo ban a peptide store?"). Each H2 is independently quotable.
5. **At least one comparison table or structured list** where the topic allows (platforms, pricing, flow types, compliant vs non-compliant phrasing). Tables are disproportionately cited by AI and win featured snippets.
6. **An entity-dense "context" section** — define the substances/regulations/standards involved (SOP D). This is where topical authority is built.
7. **Our angle / the compliant path** — every article resolves toward *how PeptideEmails does it right* (Sendlane/self-hosted, compliant copy, isolated subdomains, review-before-send). Never a hard sell; a natural bridge.
8. **FAQ block (3–6 Q&As)** using the harvested questions, marked up with `FAQPage` schema. Doubles our snippet and AI-answer surface.
9. **CTA** (SOP E).
10. **"Keep reading" — 3 internal links** to pillar + siblings (the competitor does exactly this; mirror it).

**Length & quality bar:** Match intent, not a word count. Money/comparison pages: 1,200–2,000 words with a table. Compliance references: 1,500–2,500, cited to primary sources (FDA, eCFR). Flow how-tos: 1,000–1,600 with an example email. Substance/entity pages: 1,200–1,800, scrupulously compliant (research-only framing, no disease/dosage claims — we practice what we preach). Never publish thin filler; in a thin niche, one deep post beats five shallow ones.

---

## 6. SOP C — Internal linking (the interlink discipline)

This is where most blogs fail and where we win. Enforce on **every** publish:

- **Up-link:** 1 contextual link to the article's pillar, using a descriptive anchor (not "click here").
- **Side-links:** 2–3 links to sibling spokes in the same cluster.
- **Money-link:** at least 1 link to the money hub (Pillar 1) or homepage, using commercial anchor text, from any article with commercial or comparison intent.
- **Home-link:** pillars link to the homepage; deep spokes reach the homepage within 2 clicks.
- **Anchor-text variety:** vary anchors around the target's keyword family; never use the identical anchor twice into the same URL. Keep exact-match anchors mostly for pillar→home and money-page links.
- **No orphans:** before publishing, confirm at least 2 *existing* articles link *into* the new one. Keep a link map (add a column in the CSV or a simple sheet). When you publish a new spoke, go back and add inbound links from 2 relevant older posts.
- **Depth cap:** nothing should be more than 3 clicks from the homepage.

---

## 7. SOP D — Entity richness (how we become "entity rich")

Google and AI models rank/cite pages that demonstrate they understand a topic's **entity graph** — the named things that co-occur with the subject. Bake these in deliberately.

**Core entity inventory to weave through the blog (name them explicitly, define them once, link internally on repeat use):**

- **Substances / actives:** semaglutide, tirzepatide, retatrutide, liraglutide, BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin, tesamorelin, GHK-Cu, PT-141, MOTS-c, NAD+, glutathione, AOD-9604. Class terms: GLP-1 receptor agonist, growth-hormone secretagogue, research peptide, compounded medication.
- **Platforms / tools:** Sendlane, Klaviyo, Omnisend, Mailchimp, ActiveCampaign, FluentCRM, Sendy, Mautic, Postal, self-hosted SMTP, Amazon SES, Postmark, Shopify, WooCommerce.
- **Regulations / standards / bodies:** FDA, FTC, 21 CFR 201.128, FDCA (Federal Food, Drug, and Cosmetic Act), 503A/503B compounding, DSHEA, structure/function claims, disease claims, "research use only," Certificate of Analysis (COA), Warning Letter, cGMP.
- **Deliverability / infra:** SPF, DKIM, DMARC, BIMI, dedicated IP, sending subdomain, domain warm-up, sender reputation, Google/Yahoo bulk-sender requirements, spam complaint rate, list hygiene, high-risk merchant account, payment processor.
- **Concepts / metrics:** email-attributed revenue, flows vs campaigns, replenishment/reorder cycle, LTV, deliverability rate, open/click/placement, segmentation, suppression list.

**Entity SOP per article:**
1. Identify the 8–15 entities relevant to the topic in the brief.
2. **Define each on first use** in one clean sentence (this is what AI extracts).
3. **Link internally** to the article that owns that entity (e.g. every mention of "21 CFR 201.128" links to the compliance pillar spoke that explains it).
4. Add an **`Organization` / `Article` / `FAQPage` schema** block (see SOP F) that names the entities.
5. Maintain a **glossary page** ("Peptide email marketing glossary") that defines every core entity and links out to the deep article — a powerful internal-link and AI-citation asset.

---

## 8. SOP E — CTAs by funnel stage

| Funnel stage | Article types | Primary CTA | Secondary |
|---|---|---|---|
| **BOFU** (buyer intent) | money pillar, comparisons, "platform for peptides," audience pages | "Book a free account audit" / "Schedule consultation" → LeadConnector booking link | "See an example compliant email" |
| **MOFU** (problem-aware) | flows, deliverability, infrastructure, compliance how-tos | "Get the free [flow/compliance] checklist" (email capture) | soft link to money hub |
| **TOFU** (entity/substance) | substance brand-marketing, glossary, broad guides | Newsletter / "compliance cheat-sheet" opt-in (grow *our own* list — practice what we preach) | contextual link to relevant money page |

Use the existing booking URL (`api.leadconnectorhq.com/widget/booking/...`) for BOFU. For MOFU/TOFU, stand up simple lead-magnet opt-ins so the blog *feeds our own email list* — living proof of the service.

---

## 9. SOP F — Technical & schema checklist (per publish)

- [ ] **Title tag** ≤ 60 chars, primary keyword front-loaded, brand suffix `| PeptideEmails`.
- [ ] **Meta description** ≤ 155 chars, includes primary keyword + the contrarian hook or benefit.
- [ ] **One H1**, logical H2/H3 hierarchy.
- [ ] **Slug** = keyword-first, hyphenated, no stopwords/dates.
- [ ] **Schema markup:** `Article` (+ author = PeptideEmails, `Organization`), `FAQPage` on the FAQ block, `BreadcrumbList`. Add `Product`/`Service` schema on the money hub.
- [ ] **OG + Twitter tags** + a branded OG image per post.
- [ ] **Internal links** per SOP C (verified, no broken).
- [ ] **External citations** to primary sources (FDA.gov, eCFR, platform docs) — signals trust; open in new tab, `rel` as appropriate.
- [ ] **Image alt text** with descriptive, entity-aware phrasing.
- [ ] **Mobile render + Core Web Vitals** pass (Next.js/static — keep it fast).
- [ ] **Added to XML sitemap**, submitted in Search Console.
- [ ] **Canonical** set; no accidental duplicate of a `.co`/`.com` confusion — reinforce brand ("our only site is peptideemails.com").
- [ ] **Row updated** in `01-article-roadmap.csv` → status = Published, publish date, live URL, inbound links added.

---

## 10. SOP G — Cadence, measurement & iteration

**Weekly:** publish per wave cadence; add inbound links from 2 older posts to each new post; log status in the CSV.

**Monthly review (Search Console + GA):**
- Which posts get impressions but low CTR? → rewrite title/meta.
- Which posts rank #5–15? → add depth, internal links, refresh → push to page 1. (Biggest ROI move in a thin niche.)
- Which posts convert to bookings/opt-ins? → build 2–3 more spokes around that cluster next.
- Track **AI citations**: periodically ask ChatGPT/Perplexity/Gemini the buyer questions ("best email platform for a peptide brand," "will Klaviyo ban peptides") and see if we're cited. This is a core KPI here, not an afterthought.

**Quarterly:** refresh the flagship comparison and compliance pages (dates, pricing, regulation changes). Re-run keyword validation to catch new substance entities (the peptide space moves fast — e.g. new GLP-1s) and spin up entity pages early to own them before competition arrives.

**North-star KPIs:** (1) # of cluster keywords where we rank top 3, (2) # of AI assistants that cite peptideemails.com for the core buyer questions, (3) blog-sourced booking calls + opt-ins, (4) money-hub internal-link equity.

---

## 11. Guardrails (non-negotiable — we sell compliance, so we must model it)

- **Never publish a disease claim, dosage instruction, or consumption testimonial** in our own content — including substance/entity articles. Use research-only / brand-owner-education framing throughout. Our blog is a live demonstration of the compliant standard we sell.
- **Cite primary sources** for every compliance/regulatory claim. Do not paraphrase the FDA loosely.
- **Reinforce brand identity** ("our only website is peptideemails.com") to defend against the `.co` competitor and any impersonation.
- **Don't over-optimize anchors** — natural, varied internal linking only; this niche is small and manipulative patterns stand out.

---

*Next: open [`01-article-roadmap.csv`](01-article-roadmap.csv) for the sequenced 100 articles, and [`02-content-architecture.md`](02-content-architecture.md) for the full interlink + entity map.*
